Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 7/20 | 0.74 |
| ▸ | MGAM | O43451 | 5/20 | 0.74 |
| ▸ | GLA | P06280 | 3/20 | 0.74 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | AGL | P35573 | 2/20 | 0.68 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.68 |
| ▸ | GBA1 | P04062 | 1/20 | 0.68 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nojirimycin SCHEMBL24518012 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL11239684 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL18819521 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL140917 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL25084034 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL13298780 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL2265529 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL14654237 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL1469250 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL9379987 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221357-A1 | METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221357-A1 | METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | GAA, MAN2B1, MAN1B1 | FUCA1 79/4885MGAM 9/4885GLA 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.